Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

Autres documents

Y0001030

Lamotrigine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C9H7Cl2N5
Numéro CAS:
84057-84-1
Poids moléculaire :
256.09
Numéro MDL:
MFCD00865333
Code UNSPSC :
41116107
ID de substance PubChem :
329831227
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

lamotrigine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

Clé InChI

PYZRQGJRPPTADH-UHFFFAOYSA-N

Informations sur le gène

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamotrigine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Anticonvulsant.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001085

Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001031

Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001032

Acide 2,3-dichlorobenzoique, European Pharmacopoeia (EP) Reference Standard

1356778

Acide 2,3-dichlorobenzoique, United States Pharmacopeia (USP) Reference Standard

1356790

Lamotrigine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1356789

Lamotrigine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1368

Acide 2,3-dichlorobenzoique, Pharmaceutical Secondary Standard; Certified Reference Material

BP1097

Lamotrigine, British Pharmacopoeia (BP) Reference Standard

PHR8729

Lamotrigine Related Compound C, certified reference material, pharmaceutical secondary standard

PHR8730

Lamotrigine Related Compound D, certified reference material, pharmaceutical secondary standard

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Carbamazepine powder

Sigma-Aldrich

C4024

Carbamazepine

Crystal T Clark et al.
The American journal of psychiatry, 170(11), 1240-1247 (2013-11-05)
Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder. The authors present new data on serial serum levels of lamotrigine in pregnant patients on lamotrigine monotherapy. They also review the epilepsy
Stacey Shim et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)
Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.
Shai Sandalon et al.
Experimental eye research, 115, 47-56 (2013-07-03)
Voltage gated sodium channels (Nav), are proposed mediators of neuronal damage in ischemic and excitotoxicity disease models. We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models. Additionally, expression of the
Chaitali Ghosh et al.
Epilepsia, 54(9), 1562-1570 (2013-07-20)
Brain drug bioavailability is regulated by the blood-brain barrier (BBB). It was recently suggested that cytochrome P450 (CYP) enzymes could act in concert with multidrug transporter proteins to regulate drug penetration and distribution into the diseased brain. The possibility that
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique